Byung-June Park’s Post

Akeso Published P-Ia/Ib Study (COMPASSION-01) Results of Cadonilimab for Solid Tumors in Cell Reports Medicine Shots: The P-Ia/Ib study evaluating cadonilimab (PD-1/CTLA-4 bispecific Ab) in patients with advanced solid tumors The results showed that cadonilimab reached a dose of 25mg/kg, q3w without encountering the MTD, occurrence of sev. irAE with a grade of ≥3 was 6.7%. The treatment showed a favorable safety & tolerability profile, and tumor response was seen in PD-L1+ and PD-L1-solid tumor populations indicating unique efficacy advantages over PD-1/PD-L1 mAb & may have a broader range of potential indications The therapy was found to have a favorable toxicity profile with promising efficacy. Cadonilimab is a bispecific Ab targeting PD-1 & CTLA-4. The company has conducted a series of 60+ clinical studies globally for solid tumors About Cadonilimab(PD-1/CTLA-4 bispecific antibody) Cadonilimab is a first-in-class bispecific antibody that targets both PD-1 and CTLA-4 developed by Akeso. It is a symmetric tetravalent bispecific antibody with a crystallizable fragment (Fc)-null design. In addition to demonstrating biological activity similar to that of the combination of CTLA-4 and PD-1 antibodies, cadonilimab possesses higher binding avidity in a high-density PD-1 and CTLA-4 setting than in a low-density PD-1 setting, while a mono-specific anti-PD-1 antibody does not demonstrate this differential activity. With no binding to Fc receptors, cadonilimab shows minimal antibody-dependent cellular cytotoxicity, antibody-dependent cellular phagocytosis, and interleukin-6 (IL-6)/IL-8 release. These features all likely contribute to significantly lower toxicities of cadonilimab observed in the clinic.  #solidtumors #clinicaltrials

Sonnet BioTherapeutics, Inc. used their proprietary fully human albumin binding platform technology to create SON-1010, a recombinant, single-chain, unmodified human rIL-12 joined by a flexible ([Gly4Ser]5) linker to the albumin-binding domain of a single-chain antibody fragment (FHAB). A newly published paper describes the Phase 1 data for this molecule. The conclusion: SON-1010, a novel presentation for rIL-12, was safe and well-tolerated in healthy volunteers up to 300 ng/kg. Its extended half-life leads to a prolonged but controlled IFNγ response, which may be important for tumor control in patients. https://lnkd.in/enMmKfsV

Proud to have been able to contribute to this research. Another great article, assessing ADC and recombinant photo-activated therapeutic efficacy for light-accessible and light-inaccessible tumors. https://lnkd.in/dFwTibUM

Altamira Therapeutic's AM-411 is a promising new #RNA-based therapy for #rheumatoidarthritis (RA). AM-411 targets a key inflammation checkpoint in the NF-κB signaling pathway, which plays a central role in RA. In preclinical studies, AM-411 was shown to effectively reduce inflammation and protect against bone erosions in a mouse model of RA. This intravenously administered nanoparticle was also well-tolerated, with no signs of systemic side effects. AM-411 has the potential to provide patients with a more effective and safer treatment option than current therapies. Learn more about our RNA programs here: https://bit.ly/3JjIBix #Science #RNATherapeutics

Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2–Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2–Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial https://lnkd.in/ep2CdfjZ

Another milestone not only for solid tumors and #allogeneic #NK #celltherapy, but also for cryopreserved starting material! The #cryopreservation process allows to maintain significant cellular cytotoxicity, and potentially making hundreds of thousands of #NKcell doses from a single donor. Learn how CPC Services can help your #clinicaltrial patient sample processing and cryopreservation and storage of starting material. www.cpcservices.com https://lnkd.in/eSPurzXs #immunotherapy #cancerresearch #clinicalresearch

What is tumor fraction and why should you incorporate it into your clinical trial? Tumor fraction (TF) is the proportion of cfDNA (cell-free DNA) that is ctDNA (circulating tumor DNA). In other words, from all the free-floating DNA in your blood, how much of it is from the tumor. With more cancerous cells in the body, the TF increases. So this is a marker of the elimination or progression of a cancer. It's measured by looking at copy number alterations, variant allele frequency, length of the DNA fragments, germline alterations, and clonal hematopoietic alterations. Guardant Health also even includes DNA methylation! Most ctDNA providers calculate it. It's not tied to any particular aberration, making it a useful marker to monitor how your patients are doing on the clinical trial. Suitable for all types of therapies- biologics, immunotherapeutics, targeted agents, and non-targeted agents. In fact, Tempus AI recently published a study demonstrating that TF measured up to six months after the start of Checkpoint Inhibitor therapy was predictive of efficacy (ref in comments). As well as a monitoring biomarker, it has uses for predictive biomarkers too. It helps to identify cases where the tumor fraction is too low to identify a mutation, enabling you to reflex to a tissue biopsy. It also enables you to estimate the heterogeneity of a mutation. Are you convinced? #biomarkers #ctDNA #drugdevelopment Tempus AI Predicine Foundation Medicine Guardant Health

This recent review of the latest clinical developments in GBM (immunotherapy and targeted approaches) offers interesting perspectives for early drug discovery and development: 🎯 Improve drug delivery system 🤝 consider combos, including immune combination therapies and better explore interaction between SoC and your lead before clinical trials. 💻 huge need for big data technologies and intelligent experimental platforms to overcome tumor heterogeneity (inter patient, intra-tumor and over recurrence) as well as the complex role of tumor micro-environment https://lnkd.in/e2XpTHW6

Check out AACR 2023 poster #2548 to see a great example of using our BioIVT PBMCs in combination with 3D cell culture to aid in anti-cancer therapy development, with the poster showing that: 1. Direct activation of T cells produced a significant increase in cytotoxicity compared to general activation using no target cells, whereas a diminishing effect was evident if the target cells were co-cultured with fibroblasts during the activation process. 2. The 3D cell model was proven to maintain superior cell health throughout long kinetic runs compared to 2D cell models. 3. Cytotoxicity may be quantified using propidium iodide or brightfield (label-free) methods

Altamira Therapeutics is breaking barriers in #RNATherapeutics with our OligoPhore™ / SemaPhore™ technology. Our versatile system complexes therapeutic RNAs with a proprietary peptide to create nanoparticle formulations. These formulations enable systemic delivery of therapeutic RNA to tissues affected by leaky vasculature, a common feature in solid tumors and specific inflammatory conditions. Our mission extends beyond innovation; it's about creating real-world impact. We plan to advance our flagship programs to IND/Phase I and leverage the OligoPhore™ / SemaPhore™ platforms through collaboration with partners in well-defined additional therapeutic areas. Learn more here: https://bit.ly/3JjIBix #Science #mRNA #siRNA